Hematology
Conference Coverage
Armored CAR T cells elicit responses in NHL patients
NATIONAL HARBOR, MD. – ICTCAR014, a dominant negative PD-1 armored CAR T-cell therapy, produced responses in 12 of 13 non-Hodgkin lymphoma...
News
Levofloxacin prophylaxis improves survival in newly diagnosed myeloma
Levofloxacin looks like a promising addition to therapy, but the researchers cautioned that antibiotic resistance must be considered.
Conference Coverage
Targeted agents vs. chemoimmunotherapy as first-line treatment of CLL
SAN FRANCISCO – Experts debate the role of chemoimmunotherapy as first-line treatment of chronic lymphocytic leukemia.
News
Stem cells gene edited to be HIV resistant treat ALL, but not HIV
Conference Coverage
Hematocrit (HCT) Levels and Thrombotic Events Among US Veterans With Polycythemia Vera
Digital Edition
Abstracts Presented at the 2019 AVAHO Annual Meeting
September 20-22, 2019 ► Minneapolis, MI
Conference Coverage
Standardization of the Discharge Process for Inpatient Hematology and Oncology
Conference Coverage
Investigation of Outpatient Infusion Space Utilization to Increase Access to Same-Day Transfusion for Hematology/Oncology Patients
Conference Coverage
Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation in a Veteran Population
Conference Coverage
Ibrutinib-rituximab induction yields ‘unprecedented’ responses in MCL
LUGANO, SWITZERLAND – In patients younger than 65 years old, two cycles of ibrutinib and rituximab followed by four cycles of chemotherapy...
